A population-based series of uterine carcinosarcomas with long-term follow-up

References

• Tavassoli FA, Devilee P, editors. World Health Organization classification of tumours. In: Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.
   Google Scholar
• Disaia PJ, Creasman WT. Sarcoma of the uterus. In: Disaia PJ, Creasman WT, editors. Clinical gynecologic oncology. St. Louis: Mosby; 2002.
   Google Scholar
• Livi L, Paiar F, Shah N, Blake P, Villanucci A, Amunni G, et al. Uterine sarcoma: Twenty-seven years of experience. Int J Radiat Oncol Biol Phys 2003;57:1366–73.
   PubMed Web of Science ®Google Scholar
• Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currei JL, et al. Prognostic factors in early stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993;71:1702–9.
   Google Scholar
• Chi DS, Mychalczak B, Saigo PE, Recigno J, Brown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 1997;65: 493–8.
   PubMed Web of Science ®Google Scholar
• WHO. Pathology and genetics of tumors of the breast and female genital organs. Lyon: IARC Press;2003.
   Google Scholar
• Benoit L, Arnould L, Cheynel N, Goui S, Collin F, Fraisse J, et al. The role of surgery and treatment trends in uterine sarcoma. Eur J Surg Oncol 2005;31:434–42.
   PubMed Web of Science ®Google Scholar
• Arrastia CD, Fruchter RG, Clark M, Maiman M, Remy JC, Macaset M, et al. Uterine carcinosarcomas: Incidence and trends in management and survival. Gynecol Oncol 1997;65: 158–63.
   PubMed Web of Science ®Google Scholar
• Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao S-Y, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990; 9:1–9.
   PubMed Web of Science ®Google Scholar
• Villena-Heinsen C, Diesing C, Fischer D, Griesinger D, Maas G, Diedrich N, et al. Carcinosarcomas – a retrospective analysis of 21 patients. Anticancer Res 2006;26:4817–23.
   PubMed Web of Science ®Google Scholar
• Pautier P, Rey A, Haie-Meder C, Kerbrat P, Dutel JL, Gesta P, et al. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: Results of a case-control study with radiotherapy alone. Int J Gynecol Cancer 2004;14: 1112–7.
   PubMed Web of Science ®Google Scholar
• Odunsi K, Moneke V, Tammela J, Ghamande S, Seago P, Driscoll D, et al. Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: Results of long-term follow-up. Int J Gynecol Cancer 2004;14: 659–64.
   PubMed Web of Science ®Google Scholar
• Nordal RR, Kristensen GB, Stenwig AE, Nesland JM, Pettersen EO, Tropé CG. An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol Oncol 1997;67: 316–21.
   PubMed Web of Science ®Google Scholar
• Sorbe B, Johansson B. Prophylactic pelvic irradiation as part of primary therapy in uterine sarcomas. Int J Oncol 2008; 32:1111–7.
   PubMed Web of Science ®Google Scholar
• Chiyoda T, Tsuda H, Tanaka H, Kataoka F, Nomura H, Nishimura S, et al. Expression profiles of carcinosarcomas of the uterine corpus – are these similar to carcinoma or sarcoma?Genes Chromosomes Cancer 2012;51:229–39.
   PubMed Web of Science ®Google Scholar
• Morice P, Rodrigues A, Pautier P, Rey A, Camatte S, Atallah D, et al. Surgery for uterine sarcoma: Review of the literature and recommendations for the standard surgical procedure. Gyn Obstet Fert 2003;31:147–50.
   PubMedGoogle Scholar
• Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 2004;93:204–8.
   PubMed Web of Science ®Google Scholar
• Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcomas in a high risk population. Eur J Surg Oncol 2001;27: 282–5.
   PubMed Web of Science ®Google Scholar
• Ferrer F, Sabater S, Farrus B, Guedea F, Rovirosa F, Anglada L, et al. Impact of radiotherapy on local control and survival in uterine sarcomas: A retrospective study from the Group Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 1999;44:47–52.
   PubMed Web of Science ®Google Scholar
• Knocke TH, Kucera H, Dorfler D, Pokrajac B, Potter R. Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer 1998;83:1972–9.
   PubMed Web of Science ®Google Scholar
• Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcomas. Gynecol Oncol 1997;65: 493–8.
   PubMed Web of Science ®Google Scholar
• Kushner DM, Webster KD, Belinson JL, Rybicki LA, Kennedy AW, Markman M. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. Gynecol Oncol 2000;78:221–7.
   PubMed Web of Science ®Google Scholar
• Toyoshima M, Akahira J, Matsunaga G, Niikura H, Ito K, Yaegashi N, et al. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcomas of the uterus. Gynecol Oncol 2004;94: 774–8.
   PubMed Web of Science ®Google Scholar
• Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcomas (CS) of the uterus. Gynecol Oncol 2007;107:177–85.
   Google Scholar
• Menczer J, Levy T, Piura B, Chetrit A, Altaras M, Meirovitz M, et al. A comparison between different postoperative modalities of uterine carcinosarcomas. Gynecol Oncol 2005;97: 166–70.
   PubMed Web of Science ®Google Scholar
• Kanjeekal S, Chambers A, Fung FMK, Verma S. Systematic therapy for advanced uterine sarcoma: A systematic review of the literature. Gynecol Oncol 2005;97:624–37.
   PubMed Web of Science ®Google Scholar
• Galaal K, Godfrey K, Naik R, Kucukmetin A, Bryant A. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcomas. Cochrane Database Syst Rev 2011;19:CD006812.
   Google Scholar
• Makker V, Abu-Rustum NR, Alektiar KM, Aghajanian CA, Zhou Q, Iasonos A, et al. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I–IV uterine carcinosarcomas. Gynecol Oncol 2008;111:249–54.
   PubMed Web of Science ®Google Scholar
• McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002;12:687–90.
   PubMed Web of Science ®Google Scholar
• Einstein MH, Klobocista M, Hou JY, Lee S, Mutyala S, Mehta K, et al. Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecol Oncol 2012;124:26–30.
   PubMed Web of Science ®Google Scholar
• Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA. EGFR expression and HER2/neu overexpression/ amplification in endometrial carcinosarcomas. Gynecol Oncol 2006;100:101–6.
   PubMed Web of Science ®Google Scholar
• Raspollini MR, Susini T, Amunni G, Paglierani M, Castiglione F, Garbini F, et al. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: A marker for potential molecularly targeted treatment?Int J Gynecol Cancer 2006;16:416–22.
   PubMed Web of Science ®Google Scholar
• Gurumurthy M, Somoye G, Cairns M, Parkin DE. An update on the management of uterine carcinosarcomas. Obstet Gynecol Surv 2011;66:710–6.
   PubMed Web of Science ®Google Scholar